Pharmacokinetic Study of Deferiprone in Paediatric Patients

Inclusion Criteria: * Patients in a chronic transfusional program who have received at least 150 ml/kg/year of packed red blood cells (corresponding approximately to 12 transfusions) and on current treatment with DFO, DFX, DFP; aged from 1 month to less than 6 years; or * Patients naïve to any chelation treatment who have received not less than 150 ml/kg of packed red blood cells (corresponding to approximately 12 transfusions) and have ferritin levels \> 800 ng/mL, aged from 1 month to less than 6 years; or * Patients who meet the transfusion criteria (150 ml/kg/year corresponding approximately to 12 transfusions) and have known intolerance or contraindication to DFO And if all of the following criteria apply: * Patients affected by any hereditary haemoglobinopathies requiring chronic transfusion therapy including but not limited to thalassaemia and sickle cell disease * Written informed consent obtained from their legal guardian on the patient's behalf in accordance with the national legislations. According to his/her capability, patient's informed assent will be collected Exclusion Criteria: * Patient with known intolerance or contraindication to the trial treatment * Patient with Hb levels less than 8g/dl (entry may be delayed until values return to normal) * Patient with platelet count \<100.000/mm3 or absolute neutrophil count \<1.500/mm3 (entry may be delayed until values return to normal) * Patient with evidence of abnormal liver function (ALT level \>5 times the…